Related Experiment Video
Updated: Jul 10, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Bacillus Calmette-Guerin and bladder cancer
1Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. azadrazack@gmail.com
Asian Journal of Surgery
|October 27, 2007
Summary
Intravesical bacillus Calmette-Guerin (BCG) immunotherapy is highly effective in reducing bladder cancer recurrence. This review details BCG
Area of Science:
- Oncology
- Immunology
- Urology
Background:
- Bladder cancer, particularly transitional cell carcinoma (TCC), is a common malignancy in men.
- Superficial TCC, which has not invaded beyond the lamina propria, is characterized by a high rate of recurrence.
- Current treatment strategies aim to minimize the risk of TCC recurrence and progression.
Purpose of the Study:
- To provide a comprehensive review of bacillus Calmette-Guerin (BCG) in bladder cancer treatment.
- To emphasize the indications for using intravesical BCG therapy.
- To elucidate the mechanism of action by which BCG reduces tumor recurrence and progression.
Main Methods:
- This article is a general review of existing literature on BCG immunotherapy for bladder cancer.
- It synthesizes information on the efficacy, indications, and mechanisms of BCG treatment.
- Focuses on BCG's role in managing superficial transitional cell carcinoma.
Main Results:
- Intravesical BCG is the most successful treatment to date for reducing the recurrence rate of superficial bladder cancer.
- BCG immunotherapy represents a significant advancement in cancer treatment, demonstrating broad efficacy across various malignancies.
- The review highlights BCG's established role in preventing TCC recurrence and progression.
Conclusions:
- Intravesical BCG is a cornerstone therapy for non-muscle-invasive bladder cancer, significantly reducing recurrence and progression.
- Understanding BCG's mechanism of action is crucial for optimizing its use in bladder cancer immunotherapy.
- BCG remains one of the most successful immunotherapies in oncology.
Related Concept Videos
01:23Urinary Bladder
The urinary bladder is a hollow, muscular sac that temporarily stores urine before it is expelled from the body. It can hold approximately 600 mL of urine prior to micturition. The bladder is retroperitoneal and located behind the pubic symphysis in the pelvic floor.
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
01:28Microbiota of the Urogenital Tract
The human urogenital system, once thought to be sterile in healthy individuals, is now recognized as a complex microbial habitat. Advancements in molecular sequencing techniques have revealed that even in healthy adults, the kidneys and bladder harbor microbial populations similar to those found in the distal urethra, albeit in much lower abundance. These resident microorganisms, while generally innocuous, can become opportunistic pathogens under conditions that alter the urogenital...